BioCentury

8:00 AM GMT, Dec 10, 2001
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Cash only, please

Stock is often the currency of choice in life science acquisitions, as CEOs like to leave the cash untouched to ensure they have enough working capital to fund the combined entity. But Cephalon Inc. is forking over $450 million in cash for Group Lafon, even though CEPH's shares have

Read the full 499 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.